Drug application
ORAPRED (PREDNISOLONE SODIUM PHOSPHATE)
Drugs@FDA ANDA 075117 · CONCORDIA PHARMS INC
Key facts
| Drug name | ORAPRED |
|---|---|
| Active ingredients | PREDNISOLONE SODIUM PHOSPHATE |
| Application type | ANDA |
| Application number | 075117 |
| Company | CONCORDIA PHARMS INC |
| Dosage forms | SOLUTION, ORAL |
| Strength | EQ 15MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** |
| Marketing status | Discontinued |
| Reference listed drug | No |
| Latest submission status date | Dec 14, 2000 |
At a glance
- 1–9 Submissions
- 1–9 Supplements
- 1–9 Label versions
- 1–9 Products
- None Therapeutic equivalents
- Yes FDA letters on file
- Yes FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: